We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seelos Therapeutics Inc | NASDAQ:SEEL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.055 | -4.89% | 1.07 | 1.06 | 1.20 | 1.1828 | 1.06 | 1.12 | 126,517 | 01:00:00 |
| | |
Per Share and
Accompanying Common Warrant |
| |
Per Pre-Funded
Warrant and Accompanying Common Warrant |
| |
Total
|
| |||||||||
Public offering price
|
| | | $ | 1.32 | | | | | $ | 1.319 | | | | | $ | 5,547,578.11 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.0924 | | | | | $ | 0.09233 | | | | | $ | 388,330.47 | | |
Proceeds to us, before expenses
|
| | | $ | 1.2276 | | | | | $ | 1.2267 | | | | | $ | 5,159,247.64 | | |
PROSPECTUS SUPPLEMENT
|
| |
Page
|
| |||
| | | | S-1 | | | |
| | | | S-2 | | | |
| | | | S-8 | | | |
| | | | S-11 | | | |
| | | | S-17 | | | |
| | | | S-19 | | | |
| | | | S-20 | | | |
| | | | S-21 | | | |
| | | | S-22 | | | |
| | | | S-24 | | | |
| | | | S-27 | | | |
| | | | S-31 | | | |
| | | | S-31 | | | |
| | | | S-32 | | | |
| | | | S-32 | | |
PROSPECTUS
|
| |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 8 | | | |
| | | | 43 | | | |
| | | | 45 | | | |
| | | | 46 | | | |
| | | | 52 | | | |
| | | | 59 | | | |
| | | | 64 | | | |
| | | | 65 | | | |
| | | | 68 | | | |
| | | | 70 | | | |
| | | | 70 | | | |
| | | | 70 | | | |
| | | | 71 | | |
Product
|
| |
Indication
|
| |
Development
Phase |
| |
Development Status
|
|
SLS-002
Intranasal Racemic Ketamine |
| |
Acute Suicidal Ideation and Behavior (“ASIB”) in Major Depressive Disorder (“MDD”)
|
| |
Phase II
|
| |
Completed open-label patient enrollment and announced the initial topline data from Part 1 of the proof-of-concept (“PoC”) study on May 17, 2021; enrollment of Part 2 of a Phase II study closed in June 2023; topline data for Part 2 announced on September 20, 2023
|
|
SLS-005
IV Trehalose |
| |
Amyotrophic Lateral Sclerosis (“ALS”)
|
| |
Phase II/III
|
| |
Completed enrollment of final participants in February 2023 in the registrational study; data readout expected in late 2023
|
|
| | |
Spinocerebellar Ataxia (“SCA”)
|
| |
Phase IIb/III
|
| |
Announced dosing of the first participant in the registrational study in October 2022; enrollment of additional patients temporarily paused on March 29, 2023
|
|
| | |
Huntington’s Disease (“HD”) and Alzheimer’s Disease (“AD”)
|
| |
Phase II
|
| |
Obtaining biomarker activity
|
|
SLS-004
Gene Therapy |
| |
Parkinson’s Disease (“PD”)
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing; announced partial results from a study demonstrating downregulation of α-synuclein in December 2022; currently analyzing data while temporarily pausing additional spend
|
|
Product
|
| |
Indication
|
| |
Development
Phase |
| |
Development Status
|
|
SLS-007
Peptide Inhibitor |
| |
PD
|
| |
Pre-IND
|
| |
Preclinical study completed and analysis of the results ongoing; next steps for development of this program will be decided in concert with SLS-004 results and readouts, as both target the same pathway upstream; temporarily pausing additional spend
|
|
SLS-009 | | |
HD, AD, ALS
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing
|
|
|
Public offering price per share of common stock and accompanying Common Warrant
|
| | | | | | | | | $ | 1.32 | | |
|
Net tangible book value per share as of September 30, 2023
|
| | | $ | (5.72) | | | | | | | | |
|
Increase in net tangible book value per share attributable to the issuance of an aggregate
of 273,134 shares of our common stock issued to the holder of the Note to satisfy principal and interest payments thereunder between October 5, 2023 and November 24, 2023 and the repayment of $0.5 million in principal amount of the Note in cash on November 9, 2023 |
| | | $ | 0.58 | | | | | | | | |
|
Pro forma net tangible book value per share as of September 30, 2023
|
| | | $ | (5.14) | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | 1.92 | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share as of September 30, 2023, after giving effect to this offering
|
| | | | | | | | | $ | (3.22) | | |
|
Dilution per share to investors participating in this offering
|
| | | | | | | | | $ | 4.54 | | |
Underwriter
|
| |
Number of
Shares of Common Stock and Accompanying Common Warrants |
| |
Number of
Pre-Funded Warrants and Accompanying Common Warrants |
| ||||||
Titan Partners Group LLC, a division of American Capital Partners, LLC
|
| | | | 1,781,934 | | | | | | 2,422,612 | | |
Total | | | | | 1,781,934 | | | | | | 2,422,612 | | |
| | |
Per Share and
Common Warrant |
| |
Per Pre-Funded
Warrant and Common Warrant |
| |
Total
|
| |||||||||
Public offering price
|
| | | $ | 1.32 | | | | | $ | 1.319 | | | | | $ | 5,547,578.11 | | |
Underwriting discounts and commissions (7.0%)
|
| | | $ | 0.0924 | | | | | $ | 0.09233 | | | | | $ | 388,330.47 | | |
Proceeds to us, before fees and expenses
|
| | | $ | 1.2276 | | | | | $ | 1.2267 | | | | | $ | 5,159,247.64 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 8 | | | |
| | | | 43 | | | |
| | | | 45 | | | |
| | | | 46 | | | |
| | | | 52 | | | |
| | | | 59 | | | |
| | | | 64 | | | |
| | | | 65 | | | |
| | | | 68 | | | |
| | | | 70 | | | |
| | | | 70 | | | |
| | | | 70 | | | |
| | | | 71 | | |
|
Product
|
| |
Indication
|
| |
Development Phase
|
| |
Development Status
|
|
|
SLS-002
Intranasal Racemic Ketamine |
| |
Acute Suicidal Ideation and
Behavior (ASIB) in Major Depressive Disorder (MDD) |
| |
Proof of
Concept |
| |
Startup activities initiated
|
|
|
SLS-005
IV Trehalose |
| |
Sanfilippo Syndrome
Amyotrophic Lateral Sclerosis (ALS) |
| |
Phase II
Phase IIb/III |
| |
Collecting Natural History Data Startup activities for clinical
study |
|
|
SLS-004
Gene Therapy |
| |
Parkinson’s Disease (PD)
|
| |
Phase II
|
| |
Preclinical studies to commence
soon |
|
|
SLS-006
Partial Dopamine Agonist |
| |
Parkinson’s Disease (PD)
|
| |
Phase II/III
|
| |
Evaluating studies to advance
into late stage trials |
|
|
SLS-007
Peptide Inhibitor |
| |
Parkinson’s Disease (PD)
|
| |
Pre-IND
|
| |
Preclinical data expected in
early 2021 |
|
|
SLS-008
CRTh2 Antagonist |
| |
Pediatric Esophagitis, Asthma,
Atopic Dermatitis |
| |
Pre-IND
|
| |
Formulation work underway
|
|
1 Year Seelos Therapeutics Chart |
1 Month Seelos Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions